Revvity (NYSE:RVTY) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Revvity (NYSE:RVTY) posted its quarterly earnings data on Tuesday. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08, Zacks reports. The company had revenue of $728.90 million for the quarter, compared to the consensus estimate of $694.73 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm’s revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 earnings per share.

Here are the key takeaways from Revvity’s conference call:

• Revvity exceeded expectations in Q3, delivering 7% pro forma organic growth, 29.4% adjusted operating margins, and adjusted EPS of $1.37, $0.08 above the midpoint of its guidance.
• Life sciences organic growth reached 9%, led by high-single-digit reagent growth, mid-single-digit instrument growth, and upper-teens Signals Software growth. Management cited improving pharma and biotech demand, expanding AI-related activity, and growing instrument backlogs, particularly in high-content screening.
• The company raised its full-year outlook to approximately 5% pro forma organic growth and $5.40–$5.45 adjusted EPS, while increasing its operating-margin forecast to 28.8%. Efficiency initiatives and favorable mix are supporting more than 40% incremental margins.
• Diagnostics grew 5% organically, with margins reaching 29.9%; excluding the China immunodiagnostics business targeted for divestiture, margins exceeded 30%. Revvity also launched a type 1 diabetes screening assay in Europe, but reproductive health remains constrained by weak Chinese birth rates.
• Management expects some moderation in Q4 growth, partly because reagent bulk orders shifted into Q3 and Signals Software growth is expected to slow from the high teens to the mid-teens. AI demand is broadening but remains in its early stages, and the company expects no share repurchases in its Q4 guidance.

Revvity Price Performance

NYSE RVTY opened at $163.55 on Wednesday. Revvity has a 12 month low of $81.22 and a 12 month high of $171.74. The stock has a market cap of $18.25 billion, a price-to-earnings ratio of 77.88, a PEG ratio of 2.76 and a beta of 1.08. The company’s 50 day moving average is $145.89 and its two-hundred day moving average is $112.62. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Shareholders of record on Friday, January 22nd will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, January 22nd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Insider Buying and Selling

In other Revvity news, insider Tajinder Vohra sold 7,330 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider directly owned 6,635 shares in the company, valued at $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider directly owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 9,045 shares of company stock valued at $1,281,439. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on RVTY shares. Bank of America reaffirmed a “neutral” rating on shares of Revvity in a report on Wednesday. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a research note on Sunday, August 16th. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. William Blair initiated coverage on Revvity in a research note on Monday, October 5th. They issued an “outperform” rating for the company. Finally, Royal Bank Of Canada started coverage on Revvity in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 target price on the stock. Five analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, Revvity has a consensus rating of “Hold” and an average price target of $124.43.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported adjusted EPS of $1.38, above analyst estimates of about $1.30, and revenue of $728.9 million versus forecasts of about $694.7 million. Revenue rose 4.3% year over year, while EPS increased from $1.18 a year earlier. Article: Revvity Edges Past Q3 2026 Estimates
• Positive Sentiment: The company raised its 2026 outlook after the quarterly beat. Reports point to Life Sciences growth, margin expansion, AI-related demand and operational execution as contributors to broad-based growth—supporting the case for continued earnings momentum. Article: Q3 Earnings Beat on Life Sciences Strength Article: AI Demand and Operational Execution
• Neutral Sentiment: Revvity reaffirmed its dividend, providing continuity for income-focused shareholders, but the announcement alone does not materially change the growth outlook. Article: Revvity Reaffirms Its Dividend
• Negative Sentiment: Valuation is a key counterweight: one report questions whether the stock is now too expensive. The provided background also shows a high P/E ratio and a share price near its 52-week high, which could leave less room for gains if growth or guidance disappoints. Article: Earnings Beat Might Change the Case for Revvity

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.